[A17-39] Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.11.2017
Project no.:
A17-39
Commission:
Commission awarded on 15.08.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Moderate to severe active rheumatoid arthritis
Hint of an added benefit for patients for whom treatment with biologic disease-modifying antirheumatic drugs (bDMARD) is indicated for the first time and who do not tolerate MTX. Other patient groups: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.